相似文献
1
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies.
Cancers (Basel). 2013 Jul 25;5(3):919-42. doi: 10.3390/cancers5030919.
2
Subchronic Toxicities of HZ1006, a Hydroxamate-Based Histone Deacetylase Inhibitor, in Beagle Dogs and Sprague-Dawley Rats.
Int J Environ Res Public Health. 2016 Nov 30;13(12):1190. doi: 10.3390/ijerph13121190.
3
Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
Curr Med Chem. 2020;27(15):2449-2493. doi: 10.2174/0929867325666181016163110.
4
An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Expert Opin Investig Drugs. 2016 Jun;25(6):687-96. doi: 10.1517/13543784.2016.1164140. Epub 2016 Mar 25.
5
Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations? delivery systems.
J BUON. 2018 Jul-Aug;23(4):846-861.
6
Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?
World J Gastroenterol. 2013 Feb 28;19(8):1173-81. doi: 10.3748/wjg.v19.i8.1173.
7
Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents.
Cancer Manag Res. 2024 Jul 22;16:855-869. doi: 10.2147/CMAR.S464245. eCollection 2024.
8
Histone deacetylase inhibitors in lymphoma.
Curr Opin Oncol. 2010 Sep;22(5):431-6. doi: 10.1097/CCO.0b013e32833d5954.
9
Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Drugs Today (Barc). 2015 Aug;51(8):491-504. doi: 10.1358/dot.2015.51.8.2362311.
10
Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Mol Carcinog. 2014 Sep;53(9):722-35. doi: 10.1002/mc.22024. Epub 2013 Mar 8.
引用本文的文献
1
A Review on Molecular Docking on HDAC Isoforms: Novel Tool for Designing Selective Inhibitors.
Pharmaceuticals (Basel). 2023 Nov 22;16(12):1639. doi: 10.3390/ph16121639.
2
Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).
Neuro Oncol. 2023 Dec 8;25(12):2262-2272. doi: 10.1093/neuonc/noad141.
3
Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond.
Curr Issues Mol Biol. 2023 Feb 27;45(3):1914-1949. doi: 10.3390/cimb45030124.
4
Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
PLoS One. 2022 Jul 8;17(7):e0271245. doi: 10.1371/journal.pone.0271245. eCollection 2022.
5
Interpatient Heterogeneity in Drug Response and Protein Biomarker Expression of Recurrent Ovarian Cancer.
Cancers (Basel). 2022 May 3;14(9):2279. doi: 10.3390/cancers14092279.
6
Methods for Hydroxamic Acid Synthesis.
Curr Org Chem. 2019;23(9):978-993. doi: 10.2174/1385272823666190424142821.
7
Synthesis, Anticancer Evaluation and Structure-Activity Analysis of Novel ()- 5-(2-Arylvinyl)-1,3,4-oxadiazol-2-yl)benzenesulfonamides.
Int J Mol Sci. 2020 Mar 23;21(6):2235. doi: 10.3390/ijms21062235.
8
HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?
Cancers (Basel). 2020 Jan 29;12(2):318. doi: 10.3390/cancers12020318.
9
Combination Therapies Targeting HDAC and IKK in Solid Tumors.
Trends Pharmacol Sci. 2018 Mar;39(3):295-306. doi: 10.1016/j.tips.2017.11.008. Epub 2017 Dec 9.
10
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma.
Diseases. 2015 Sep 29;3(4):221-252. doi: 10.3390/diseases3040221.
本文引用的文献
1
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents.
Biologics. 2013;7:47-60. doi: 10.2147/BTT.S29965. Epub 2013 Feb 25.
2
The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review.
PLoS One. 2013;8(1):e51780. doi: 10.1371/journal.pone.0051780. Epub 2013 Jan 22.
3
Recent advancements of bortezomib in acute lymphocytic leukemia treatment.
Acta Haematol. 2013;129(4):207-14. doi: 10.1159/000345260. Epub 2013 Jan 3.
4
Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.
J Clin Oncol. 2012 Sep 20;30(27):3361-7. doi: 10.1200/JCO.2011.41.2395. Epub 2012 Aug 20.
5
A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors.
Cancer Chemother Pharmacol. 2012 Sep;70(3):471-5. doi: 10.1007/s00280-012-1931-x. Epub 2012 Aug 1.
6
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.
Cancer Chemother Pharmacol. 2012 Aug;70(2):251-8. doi: 10.1007/s00280-012-1911-1. Epub 2012 Jun 29.
7
Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer.
Int J Gynecol Cancer. 2012 Jul;22(6):979-86. doi: 10.1097/IGC.0b013e31825736fd.
8
The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment.
Curr Med Chem. 2012;19(25):4218-38. doi: 10.2174/092986712802884286.
9
A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.
Clin Cancer Res. 2012 May 1;18(9):2687-94. doi: 10.1158/1078-0432.CCR-11-3165.
10
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
Anticancer Res. 2012 Mar;32(3):1027-31.
Zotero 插件
